CAYSTON® Information for Healthcare Professionals | CAYSTON® Official HCP Site

CAYSTON is indicated to improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa (Pa). Read MoreSafety and effectiveness have not been established in pediatric patients below the age of 7 years, patients with FEV1 <25% or >75% predicted, or patients colonized with Burkholderia cepacia.

  • Contact Us
  • For Patients & Caregivers
  • Full Prescribing Information
  • Indication
CAYSTON logo white
  • CLINICAL DATA
  • ABOUT CAYSTON
  • SAFETY
  • DOSING & ADHERENCE
  • PROGRAMS
  • RESOURCES
Questions? Connect with us

    EFFICACY

  • RESPIRATORY SYMPTOMS
  • FOREST PLOT
  • LUNG FUNCTION
  • DISEASE SEVERITY
  • ADULT/PEDIATRIC

    EFFICACY

  • LUNG FUNCTION
  • RESPIRATORY SYMPTOMS

    EXTENSION PHASE

  • STUDY DESIGN
  • EFFICACY RESULTS
  • SAFETY
  • AIR-CF1
    • Study Design
    • Efficacy
    • Safety
  • ACTIVE COMPARATOR
    • Study Design
    • Efficacy
    • Safety
    • Extension Phase
  • Mechanism of Action & Delivery
  • Systemic Exposure & Microbiology
  • Guidelines
  • Common Misconceptions
  • Important Safety Information
  • Taking CAYSTON
  • Restarting CAYSTON
  • ALTERA® Nebulizer System
  • Cayston Access Program®
  • ALLY® Refill Report Program
  • My Cayston Community™
  • Resources
  • Clinical Data
      AIR-CF1
    • Study Design
    • Efficacy
    • Safety
    • Active Comparator
    • Study Design
    • Efficacy
    • Safety
    • Extension Phase
  • About CAYSTON
    • Mechanism of Action & Delivery
    • Systemic Exposure & Microbiology
    • Guidelines
    • Common Misconceptions
  • Safety
    • Important Safety Information
  • Dosing & Adherence
    • Taking CAYSTON
    • Restarting CAYSTON
    • ALTERA® Nebulizer System
  • Programs
    • Cayston Access Program®
    • ALLY® Refill Report Program
    • My Cayston Community™
  • Resources
  • Contact Us
  • Questions? Connect with us

THEIR TREATMENT
SUCCESS STARTS
WITH YOU

Discover resources to support patients as
they start, restart, or stay on CAYSTON.

Discover resources to support
patients as they start, restart, or stay
on CAYSTON.

View CAYSTON clinical trial results
REOH, TREATED WITH CAYSTON
Support Your Patients
Restarting CAYSTON
Right arrow
Enroll Patients in the
Cayston Access Program®
Right arrow
Encourage Your Patients With
Helpful Support From
My Cayston CommunityTM
Right arrow
REOH, TREATED WITH CAYSTON
Support Your Patients Restarting CAYSTON
Right arrow
Enroll Patients in the Cayston Access Program®
Right arrow
Encourage Your Patients With Helpful Support From My Cayston CommunityTM
Right arrow
Tap for Important Safety Information

CAYSTON is contraindicated in patients with a known allergy to aztreonam.

Continued below
Please read the following Important Safety Information before your video begins.

INDICATION

CAYSTON is indicated to improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa (Pa). Safety and effectiveness have not been established in pediatric patients below the age of 7 years, patients with FEV1 <25% or >75% predicted, or patients colonized with Burkholderia cepacia.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of CAYSTON and other antibacterial drugs, CAYSTON should be used only to treat patients with CF known to have Pa in the lungs.

Important Safety Information and Indication

Contraindications

CAYSTON is contraindicated in patients with a known allergy to aztreonam.

INDICATION

CAYSTON is indicated to improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa (Pa). Safety and effectiveness have not been established in pediatric patients below the age of 7 years, patients with FEV1 <25% or >75% predicted, or patients colonized with Burkholderia cepacia.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of CAYSTON and other antibacterial drugs, CAYSTON should be used only to treat patients with CF known to have Pa in the lungs.

Warnings and Precautions

  • Allergic Reactions: Severe allergic reactions have been reported following administration of aztreonam for injection to patients with no known history of exposure to aztreonam. In addition, allergic reaction with facial rash, facial swelling, and throat tightness was reported with CAYSTON in clinical trials. If an allergic reaction occurs, stop administration of CAYSTON and initiate treatment as appropriate. Caution is advised when administering CAYSTON to patients if they have a history of allergy to beta-lactam antibiotics, such as penicillins, cephalosporins, and/or carbapenems, since cross-reactivity may occur.

  • Bronchospasm: Bronchospasm is a complication associated with nebulized therapies, including CAYSTON. Reduction of 15% or more in forced expiratory volume in 1 second (FEV1) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON.

  • Decreases in FEV1 After 28-Day Treatment Cycle: In clinical trials, patients with increases in FEV1 during a 28-day course of CAYSTON were sometimes treated for pulmonary exacerbations when FEV1 declined after the treatment period. Healthcare providers should consider a patient’s baseline FEV1 measured prior to CAYSTON therapy and the presence of other symptoms when evaluating whether post-treatment changes in FEV1 are caused by a pulmonary exacerbation.

  • Development of Drug-Resistant Bacteria: Prescribing CAYSTON in the absence of known Pa infection in patients with CF is unlikely to provide benefit and increases the risk of development of drug-resistant bacteria.

Adverse Reactions

  • Adverse reactions (>5%) in CAYSTON patients were cough, nasal congestion, wheezing, pharyngolaryngeal pain, pyrexia, chest discomfort, abdominal pain, and vomiting. Adverse reactions reported (<5%) in CAYSTON patients were bronchospasm and rash.

Indication

CAYSTON is indicated to improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa (Pa). Safety and effectiveness have not been established in pediatric patients below the age of 7 years, patients with FEV1 <25% or >75% predicted, or patients colonized with Burkholderia cepacia.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of CAYSTON and other antibacterial drugs, CAYSTON should be used only to treat patients with CF known to have Pa in the lungs.

Please click here to see full Prescribing Information.

Gilead logo
  • Corporate Site
  • Terms of Use
  • Privacy Policy
  • Contact Us
  • References
  • Site Map

The information contained on this site is intended for audiences in the United States only. The content on this site may not apply to non-US audiences as regulatory control, legal requirements, and/or medical practices may vary in other countries.

ALLY, CAYSTON, the CAYSTON logo, CAYSTON ACCESS PROGRAM, the CAYSTON ACCESS PROGRAM logo, GILEAD, the GILEAD logo, and MY CAYSTON COMMUNITY are trademarks of Gilead Sciences, Inc. ALTERA is a registered trademark of PARI Pharma GmbH. All other trademarks referenced herein are the property of their respective owners.

©2023 Gilead Sciences, Inc. All rights reserved. US-CAYP-0035 02/23

You are about to leave CAYSTON.com

CAYSTON.com offers links to external pages and is not responsible for any content published on the third-party website you are about to enter. Gilead has not reviewed and does not endorse any information presented on third-party websites.

Go Back Continue

Warranty Process

  1. Your patients’ first shipment of CAYSTON® (aztreonam for inhalation solution) will include the ALTERA® Nebulizer System.
  2. A nebulizer system warranty card from the manufacturer (PARI) will also be included.
  3. It is important that your patients complete the warranty card. Click below to access the PARI website, where they can submit their warranty card.
X
Continue

THE CFQ-R PROVIDES A Quantitative MEASURE OF THE PATIENT’S EXPERIENCE WITH OVERALL HEALTH, INCLUDING RESPIRATORY SYMPTOMS6,*

Selected questions from the Respiratory Domain include7,†:

  • Have you been congested?
  • Have you been coughing during the day?
  • Have you had to cough up mucus?
  • How often during the past 2 weeks have you been wheezing?
  • How often during the past 2 weeks have you had trouble breathing?
  • How often during the past 2 weeks have you woken up during the night because you were coughing?

*Each item is summed to generate a domain score and standardized. Scores range from 0 to 100, with higher scores indicating better health.6

†These questions are from the CFQ-R version for patients 14 years and older; younger children used a different questionnaire or a parent questionnaire was used. Minimum clinically important difference was not established for the child/parent questionnaire.

X
  • Full Prescribing Information
  • Patient Information
  • Important Safety Information
  • BATTLING
    PSEUDOMONAS
    AERUGINOSA (Pa)
  • CLINICAL
    STUDIES
     
  • STARTING
    CAYSTON
     
  •  
    SUMMARY
     
Interactive brochure
Interactive brochure
x
Interactive brochure
Interactive brochure

DID YOU KNOW?

These 3 bugs represent coughing, wheezing, and mucus production; 3 of the breathing symptoms you may experience if you have Pa.

x

TIP:
Do not change your dose or stop taking CAYSTON unless your healthcare provider tells you to.

x
Interactive brochure

This is how the study was designed, before it began.

x

This is also referred to as a "double-blind" study.

x

Even though people were off treatment, they were still being monitored for the study.

x
Interactive brochure

People gave answers from a 4-point scale to communicate to their doctors how they were feeling.

x

TIP:
Track how you're feeling with a daily journal. Ask yourself these questions and talk to your doctor about symptoms you're experiencing.

x
Interactive brochure

"Breathing symptoms" include wheezing, coughing, and mucus production.

x

This means that even after people stopped taking CAYSTON, they still reported an improvement in their wheezing, coughing, and mucus production compared to placebo at Day 42, though the difference was smaller.

x
Interactive brochure

Interactive brochure

It’s so important for the Pa medication to improve his FEV1 —it gives you the encouragement to keep going.


Annie (caretaker for Gareth, age 8, treated with CAYSTON)

x

Day 28 was the predetermined timepoint used to measure improvement.

x

FYI:
This means how much air can be exhaled, in liters.

x
Interactive brochure

Currently taking CAYSTON and have questions for your care team?

Download a Conversation Guide

x

IMPORTANT:
Talk to your doctor if you experience new or worsening symptoms while taking CAYSTON.

x
Interactive brochure

This is how the study was designed, before it began.

x

This means that the study was not used in the evaluation and not taken into consideration for the FDA approval of CAYSTON. The information will not be found in the package insert.

x
Interactive brochure

The 3 numbers across each treatment course were averaged to come up with the actual change in lung function.

x

Considering CAYSTON and have questions for your care team?

Download a Conversation Guide

x
Interactive brochure

This study was set up to only look at results from one time point.

x

Interactive brochure Managing CF with my care team means educating myself about treatment options and playing an active, central role as a member of my care team.

Chris Kvam

Learn how Chris talks about treatment options with his care team.

Hear from Chris

x
Interactive brochure

IMPORTANT:
Tell your doctor if you have any new or worsening symptoms while taking CAYSTON and about any side effects that bother you or that do not go away.

x
Interactive brochure

Want more tips for fitting CAYSTON into your day?

Get tips

x
Interactive brochure

Learn about dosing and administration with CAYSTON.

Get the guide

x

Watch a video about how CAYSTON and the ALTERA® Nebulizer work.

Watch now

x

See how to properly mix and store your CAYSTON treatment.

View now

x
Interactive brochure

Interactive brochure
As someone who works full-time, has a family, and likes to travel, flexibility is the key to managing my treatment regimen.


Mark


See how Mark takes his treatment on the go

x
Interactive brochure

Watch how to clean and disinfect your ALTERA Nebulizer Handset.

View now

x
Interactive brochure

Use the Cayston Access Program Enrollment Form to get started.

Download now

x

Get familiar with the resources that can help you start and stay on track with CAYSTON.

Download the Resource Guide

x
Interactive brochure

Download this Clinical Data Overview.

Download now

x

More questions about CAYSTON?

Read the FAQs

x

DID YOU KNOW?
You can get resources sent straight to your inbox.

Visit My Cayston Community

x
Interactive brochure
X
Full Prescribing Information Important Safety Information
×

Continued below
Please read the following Important Safety Information before your video begins.

INDICATION

CAYSTON is indicated to improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa (Pa). Safety and effectiveness have not been established in pediatric patients below the age of 7 years, patients with FEV1 <25% or >75% predicted, or patients colonized with Burkholderia cepacia.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of CAYSTON and other antibacterial drugs, CAYSTON should be used only to treat patients with CF known to have Pa in the lungs.

Important Safety Information and Indication

Contraindications

CAYSTON is contraindicated in patients with a known allergy to aztreonam.

INDICATION

CAYSTON is indicated to improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa (Pa). Safety and effectiveness have not been established in pediatric patients below the age of 7 years, patients with FEV1 <25% or >75% predicted, or patients colonized with Burkholderia cepacia.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of CAYSTON and other antibacterial drugs, CAYSTON should be used only to treat patients with CF known to have Pa in the lungs.

Warnings and Precautions

  • Allergic Reactions: Severe allergic reactions have been reported following administration of aztreonam for injection to patients with no known history of exposure to aztreonam. In addition, allergic reaction with facial rash, facial swelling, and throat tightness was reported with CAYSTON in clinical trials. If an allergic reaction occurs, stop administration of CAYSTON and initiate treatment as appropriate. Caution is advised when administering CAYSTON to patients if they have a history of allergy to beta-lactam antibiotics, such as penicillins, cephalosporins, and/or carbapenems, since cross-reactivity may occur.

  • Bronchospasm: Bronchospasm is a complication associated with nebulized therapies, including CAYSTON. Reduction of 15% or more in forced expiratory volume in 1 second (FEV1) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON.

  • Decreases in FEV1 After 28-Day Treatment Cycle: In clinical trials, patients with increases in FEV1 during a 28-day course of CAYSTON were sometimes treated for pulmonary exacerbations when FEV1 declined after the treatment period. Healthcare providers should consider a patient’s baseline FEV1 measured prior to CAYSTON therapy and the presence of other symptoms when evaluating whether post-treatment changes in FEV1 are caused by a pulmonary exacerbation.

  • Development of Drug-Resistant Bacteria: Prescribing CAYSTON in the absence of known Pa infection in patients with CF is unlikely to provide benefit and increases the risk of development of drug-resistant bacteria.

Adverse Reactions

  • Adverse reactions (>5%) in CAYSTON patients were cough, nasal congestion, wheezing, pharyngolaryngeal pain, pyrexia, chest discomfort, abdominal pain, and vomiting. Adverse reactions reported (<5%) in CAYSTON patients were bronchospasm and rash.

Indication

CAYSTON is indicated to improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa (Pa). Safety and effectiveness have not been established in pediatric patients below the age of 7 years, patients with FEV1 <25% or >75% predicted, or patients colonized with Burkholderia cepacia.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of CAYSTON and other antibacterial drugs, CAYSTON should be used only to treat patients with CF known to have Pa in the lungs.

Please click here to see full Prescribing Information.

Important Safety Information

×